Using transgenic mouse model of lung cancer, we showed that Zno/K* lung cancers were sensitive to combinational therapy with NF-κB inhibitor, KRAS inhibitor and PD-1 antibody. The gene discussed is NFKB1; the disease is lung carcinoma.